Key genetic code change drives common lung cancer type

byNYU Langone HealthGraphical abstract. Credit:Cancer Cell(2022). DOI: 10.1016/j.ccell.2022.11.015A team led by researchers at NYU Langone Health's Perlmutter Cancer Center has i

Updated on: December 22,2023 9

Key genetic code change drives common lung cancer type

byNYU Langone HealthGraphical abstract. Credit:Cancer Cell(2022). DOI: 10.1016/j.ccell.2022.11.015A team led by researchers at NYU Langone Health's Perlmutter Cancer Center has i

Updated on:December 22,2023 9

Lutetium Lu 177 Vipivotide Tetraxetan Provides HRQOL Benefit, Reduces Skeletal Events in mCRPC

July 9, 2023Kyle DohertyThe addition of lutetium Lu 177 vipivotide tetraxetan to standard-of-care treatment delayed time to worsening of health-related quality of life and skeletal events compared wit

Updated on: October 15,2023 205

Lutetium Lu 177 Vipivotide Tetraxetan Provides HRQOL Benefit, Reduces Skeletal Events in mCRPC

July 9, 2023Kyle DohertyThe addition of lutetium Lu 177 vipivotide tetraxetan to standard-of-care treatment delayed time to worsening of health-related quality of life and skeletal events compared wit

Updated on:October 15,2023 205

Personalised blood test could help predict which lung cancers might return

byGraeme Sneddon| News1 April 2022Patients who are at a higher risk of their lung cancer returning can be identified by a personalised blood test that is performed after treatment, accordi

Updated on: December 19,2023 24

Personalised blood test could help predict which lung cancers might return

byGraeme Sneddon| News1 April 2022Patients who are at a higher risk of their lung cancer returning can be identified by a personalised blood test that is performed after treatment, accordi

Updated on:December 19,2023 24

Adjuvant capecitabine after CRT improves survival in locally advanced nasopharynx

October 25, 2022Jason HarrisTreatment with adjuvant capecitabine following concurrent chemoradiotherapy resulted in superior failure-free survival compared with observation and CRT for patients with l

Updated on: October 17,2023 240

Adjuvant capecitabine after CRT improves survival in locally advanced nasopharynx

October 25, 2022Jason HarrisTreatment with adjuvant capecitabine following concurrent chemoradiotherapy resulted in superior failure-free survival compared with observation and CRT for patients with l

Updated on:October 17,2023 240

Unraveling of genetic mechanism behind tumor formation may improve targeted treatment for cancer patients

by Rutgers Cancer Institute of New JerseyCredit: Pixabay/CC0 Public DomainGenetic alterations in the FGFR2 gene occur in various cancer types and represent a promising target for therapies. However, c

Updated on: December 18,2023 11

Unraveling of genetic mechanism behind tumor formation may improve targeted treatment for cancer patients

by Rutgers Cancer Institute of New JerseyCredit: Pixabay/CC0 Public DomainGenetic alterations in the FGFR2 gene occur in various cancer types and represent a promising target for therapies. However, c

Updated on:December 18,2023 11

Survival is a mixed matter for deadliest of pancreatic cancers

byUniversity of California - San DiegoPancreatic cancer cells (nuclei in blue) are shown growing as a sphere encased in membranes (red). Credit: National Cancer InstitutePancreatic ductal adenoc

Updated on: December 21,2023 6

Survival is a mixed matter for deadliest of pancreatic cancers

byUniversity of California - San DiegoPancreatic cancer cells (nuclei in blue) are shown growing as a sphere encased in membranes (red). Credit: National Cancer InstitutePancreatic ductal adenoc

Updated on:December 21,2023 6

Lung cancer screening guidelines perpetuate racial disparities, study finds

Lung cancer screening guidelines perpetuate racial disparities, study findsby Krista Conger,Stanford UniversityRacial Disparities in the Eligibility-Incidence (E-I) Ratio Through the US Preventi

Updated on: October 30,2023 6

Lung cancer screening guidelines perpetuate racial disparities, study finds

Lung cancer screening guidelines perpetuate racial disparities, study findsby Krista Conger,Stanford UniversityRacial Disparities in the Eligibility-Incidence (E-I) Ratio Through the US Preventi

Updated on:October 30,2023 6

Oncolytic Virus Enables the Immune System to Attack Tumors

by Shana SpindlerOne of the most important findings in cancer research in the past two decades is that tumors can create force field-like protection against the immune system. A new study has identifi

Updated on: October 15,2023 291

Oncolytic Virus Enables the Immune System to Attack Tumors

by Shana SpindlerOne of the most important findings in cancer research in the past two decades is that tumors can create force field-like protection against the immune system. A new study has identifi

Updated on:October 15,2023 291

Comparing DNA changes in blood stem cells and leukemia cells could help pick out children with high-risk AML

Credit: Unsplash/CC0 Public DomainIn some children with acute myeloid leukemia, cancer cells have as many DNA changes as healthy blood stem cells. Researchers were surprised to find these children hav

Updated on: November 02,2023 10

Comparing DNA changes in blood stem cells and leukemia cells could help pick out children with high-risk AML

Credit: Unsplash/CC0 Public DomainIn some children with acute myeloid leukemia, cancer cells have as many DNA changes as healthy blood stem cells. Researchers were surprised to find these children hav

Updated on:November 02,2023 10

Study shows giving entire course of radiation treatment in less than a second is feasible

byPerelman School of Medicine at the University of PennsylvaniaCancer patients may one day be able to get their entire course of radiation therapy in less than a second rather than coming in for

Updated on: December 20,2023 25

Study shows giving entire course of radiation treatment in less than a second is feasible

byPerelman School of Medicine at the University of PennsylvaniaCancer patients may one day be able to get their entire course of radiation therapy in less than a second rather than coming in for

Updated on:December 20,2023 25

Pembrolizumab Active in Advanced Nasopharyngeal Carcinoma

August 29, 2017Jason HarrisPembrolizumab (Keytruda) induced an overall response rate of 25.9% and was well tolerated in patients with PD-L1–positive recurrent or metastatic nasopharyngeal carcinoma.Na

Updated on: October 24,2023 76

Pembrolizumab Active in Advanced Nasopharyngeal Carcinoma

August 29, 2017Jason HarrisPembrolizumab (Keytruda) induced an overall response rate of 25.9% and was well tolerated in patients with PD-L1–positive recurrent or metastatic nasopharyngeal carcinoma.Na

Updated on:October 24,2023 76

Banking on breakthroughs for children and young people

byPhil Prime| Interview27 September 2022A partnership between Cancer Research UK and Blood Cancer UK has resulted in the UK’s leading biomedical research resource dedicated to storing samp

Updated on: December 19,2023 15

Banking on breakthroughs for children and young people

byPhil Prime| Interview27 September 2022A partnership between Cancer Research UK and Blood Cancer UK has resulted in the UK’s leading biomedical research resource dedicated to storing samp

Updated on:December 19,2023 15